Sporozoite challenge study to assess safety, immunogenicity and protective efficacy of intravenous boosting with ChAd63 and MVA encoding ME-TRAP

Plasmodium falciparum Malaria remains a major global health problem with approximately 200 million cases and 500,000 deaths worldwide annually, mostly in African infants. Current malarial control strategies are threatened by the emergence of parasite resistance to drug treatment and resistance of the mosquito vector to certain insecticides. A deployable malaria vaccine is therefore a key strategy for reducing malaria mortality and progressing towards global eradication, but those in clinical trials are currently someway short of WHO targets. ChAd63 ME-TRAP and MVA ME-TRAP are leading candidate vaccines being developed by Adrian Hill’s group at the University of Oxford, and collaborators. Since 2007, testing of these vaccines intramuscularly in over 900 volunteers has shown them to be safe, well tolerated, and capable of delivering partial efficacy against malaria infection.

Study type: Interventional
Enrollment: 43 participants
Primary purpose: Basic Science
Allocation: Non-Randomized
Interventional Model: Parallel assignment
Masking : Open label
NCT number: NCT03707353
Phase: Phase I/II

Clinical trial registration

Vaccines

Oct 2018 — Jun 2019

United Kingdom